A mutational hotspot in AMOTL1 defines a new syndrome of orofacial clefting, cardiac anomalies, and tall stature.
Alanna StrongSoumya RaoSandra von HardenbergDong LiLiza L CoxPaul C LeeLi Q ZhangWaheed AwotoyeTamir DiamondJessica GoldCatherine GoochLord Jephthah Joojo GowansHakon HakonarsonAnne HingKathleen LoomesNicole MartinMary L MarazitaTarja MononenDavid PiccoliRolph PfundtSalmo RaskinStephen W SchererNara Lygia de Macena SobreiraCourtney VaccaroXiang WangDeborah WatsonRosanna WeksbergElizabeth BhojJeffrey C MurrayAndrew C LidralAzeez ButaliMichael F BuckleyTony RoscioliDavid A KoolenLaurie H SeaverCynthia A ProwsRolf W StottmannTimothy C CoxPublished in: American journal of medical genetics. Part A (2023)
AMOTL1 encodes angiomotin-like protein 1, an actin-binding protein that regulates cell polarity, adhesion, and migration. The role of AMOTL1 in human disease is equivocal. We report a large cohort of individuals harboring heterozygous AMOTL1 variants and define a core phenotype of orofacial clefting, congenital heart disease, tall stature, auricular anomalies, and gastrointestinal manifestations in individuals with variants in AMOTL1 affecting amino acids 157-161, a functionally undefined but highly conserved region. Three individuals with AMOTL1 variants outside this region are also described who had variable presentations with orofacial clefting and multi-organ disease. Our case cohort suggests that heterozygous missense variants in AMOTL1, most commonly affecting amino acid residues 157-161, define a new orofacial clefting syndrome, and indicates an important functional role for this undefined region.